Wilex AG as become the latest company to invest in antibody-drug conjugate technology with the proposed acquisition of Heidelberg Pharma AG, a privately-held German company with a conjugate platform. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
